#637

add Nicolas Verhoeven, PhD - Physionic - he’s a pure science guy, he doesn’t preach just dissects studies

2 Likes
#638

https://www.physionic.org

His contact page says that he’s only interested in business enquiries! :man_shrugging:

#639

maybe there is a subscriber here on this forum that can comment about it, he responds to his subscribers

2 Likes
#640
2 Likes
#641

It depends on what you are most worried about (based on evidence) … for me I’m not worried about vascular disease as I both monitor for that, and optimize my ApoB and everything else. I appreciate the mouse data on phospholipid DHA, however, I would point out that ApoE4 carriers probably respond clinically and have protection with eating fish, but not taking standard DHA supplements. The only thing that is different is that #1 You are having all the other things in fish - not just the oil, #2 It is in phospholipid form.
So I’m more worried about my brain as I have no vascular disease and can monitor for developing it - so have more fish and I’m going with the phospholipid forms of DHA, but in a mix that still has plenty of EPA.

This is simply individualized risk/benefit. Obviously, my opinion would be different for someone with heart disease and no ApoE4.

I’ll wait for more data on the phospholipid forms … and it might prove useless in the end.

3 Likes
#642

I agree that eating fish is the best way.

But what about the CVD and cancer risk in Mendelian randomization studies? Vitamin O (Omega 3) for athletes - #4 by adssx

1 Like
#643

I’ve not seen any data linking Omega 3’s to increased all cause mortality - and my personal concern is AD - and the absolute magnitude (not RR) are numbers that don’t concern me.

It does look like EPA transport into the brain is less affected in ApoE4 carriers as compared to the more significant loss of DHA transport. It also looks as though EPA does have at least come conversion to DHA in the brain.

I’ve then come across this article which is fascinating … I think the best situation is cutting the DHA amount significantly down and finding a good source of lysophosphatidylcholine-EPA as this looks to enhance brain DHA more than taking DHA directly according to the article. Now finding a good source of LPC-EPA will take some research.

5 Likes
#644

Very interesting and aligns with this paper: "Together these findings suggest that an EPA-dominant formula may provide some benefit in APOEE4 carriers with no dementia and WMLs, and DHA-dominant formulas may benefit noncarriers of APOEE4 with mild-to-moderate AD.” (ω-3 PUFA for Secondary Prevention of White Matter Lesions and Neuronal Integrity Breakdown in Older Adults A Randomized Clinical Trial 2024)

Commercially available here: Accentrate® Omega – Fenix Health Science

“Accentrate® Omega with LYSOVETA® LPC is specifically formulated with the omega-3s, LPC-EPA and LPC-DHA.”

image
image1184×848 167 KB

See also: LYSOVETA | LPC bound EPA & DHA by Aker BioMarine

1 Like
#645

Aker Biomarine gets NDI nod from FDA for brain health ingredient 2023

The Norwegian fishing and biotech company has successfully achieved New Dietary Ingredient (NDI) status from the US Food and Drug Administration for its Lysoveta. Under the NDI, Aker BioMarine can market Lysoveta at 1.5 grams/day for the general adult population.
Aker Bio has spent the last several years developing and building the clinical substantiation for Lysoveta, a novel dietary supplement for targeted delivery of lysophosphatidylcholine (LPC-EPA/DHA) derived from krill.
“I mean we started this project back in 2014, so it’s been several years of development, probably some $50 million of investment in developing a production process and then doing all the safety studies and now preparing for the commercialization of the product, so it’s quite exciting,” commented Matts Johansen, CEO, Aker BioMarine ASA.
The company, which develops krill-based ingredients for nutraceutical, aquaculture, and animal feed applications, has a supply chain that stretches from krill harvesting in Antarctic waters through its logistics hub in Montevideo, Uruguay, to its krill oil manufacturing facility in Houston, Texas.
Blood brain barrier
Aker Bio plans for supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to allow…

#646

I’ve looked at it and the only issue I have is how little EPA or DHA it has in it - and also, if we really want just LPC-EPA … probably want 500-1000 mg/day - and this is well below AND it has DHA. I’ve been unable to find a pure LPC-EPA product. Anyway, these options look to be sensible as compared to what I’m doing right now possibly. However the issue is if the LPC is better than phospholipids? If not - the NatureBell product I mentioned would be a better move if phospholipids work as well as LPC.

3 Likes
#647

Maybe 70 mg of LPC EPA is way more absorbable?

However, this recent Canadian paper is not that enthusiastic about LPC omega 3: Providing lysophosphatidylcholine-bound omega-3 fatty acids increased eicosapentaenoic acid, but not docosahexaenoic acid, in the cortex of mice with the apolipoprotein E3 or E4 allele 2025

After two months of gavage with LPC n-3, APOE3 mice showed increased levels of EPA in their cortex, but not DHA. In APOE4 mice, neither EPA nor DHA levels were significantly affected. After four months of LPC n-3, both APOE3 and APOE4 mice exhibited higher EPA levels, while changes in DHA levels were not statistically significant.

It’s a mouse model though…

3 Likes
#648

MR studies are lifelong, so the absolute risk should be pretty high. Of course it depends how long you have the exposure and what the lifetime prevalence is.

If you believe the MR data (without controlling for the FADS gene cluster), then DHA increases aortic valve stenosis controlling for LDL-c/apoB, as well as other clinically relevant increases in depression rates, lung cancer, and colorectal cancer.

1.36 (95% CI 1.10–1.68) for aortic valve stenosis (Fig. 2). None of these results, except for aortic valve stenosis, passed our multiple testing correction threshold (P < 0.006).

image

2 Likes
#649
1 Like
#650

Matt Kaeberlein got back to me: How much omega-3 do you need? - #69 by adssx

1 Like
#651

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer’s Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

2 Likes
#652

Oily fish consumption RCTs show lots of biomarker benefits.
Apob lowering, blood pressure lowering etc. Here’s one showing lower inflammation: An Oily Fish Diet Improves Subclinical Inflammation in People at High Cardiovascular Risk: A Randomized Controlled Study - PMC

I’m a sushi amd sardine addict though, so I haven’t looked at the evidence too sceptically

4 Likes
#653
2 Likes
#654

More good news for those of us working to keep our APOB / LDL-C as low as reasonably possible. Statins, for most people at least, are probably your friend.

People with low levels of low-density lipoprotein cholesterol (LDL-C) in their blood have a lower overall risk of dementia, and a reduced risk of Alzheimer’s disease specifically, according to research published in the Journal of Neurology Neurosurgery & Psychiatry.

Taking statins also provided an “additional protective effect” against the condition for those people with low levels of bad cholesterol, researchers found.

The Paper: (Open access)

Low-density lipoprotein cholesterol levels and risk of incident dementia: a distributed network analysis using common data models

Results The LDL-C levels below 70 mg/dL (1.8 mmol/L) were associated with a 26% reduction in the risk of all-cause dementia and a 28% reduction in the risk of ADRD, compared with levels above 130 mg/dL (3.4 mmol/L). For LDL-C levels below 55 mg/dL (1.4 mmol/L), there was an 18% risk reduction for both outcomes. Among those with LDL-C <70 mg/dL (<1.8 mmol/L), statin use was associated with a 13% reduction in all-cause dementia risk and a 12% decrease in ADRD risk compared with non-users.

Conclusion Low LDL-C levels (<70 mg/dL (<1.8 mmol/L)) are significantly associated with a reduced risk of dementia, including ADRD, with statin therapy providing additional protective effects. These findings support the necessity of targeted lipid management as a preventive strategy against dementia, indicating the importance of personalised treatment approaches.

2 Likes
#655

What do you mean by f.ex?

#656

f.ex. - for example; same as e.g. just that f.ex is english and e.g. (exempli gratia) is latin, both mean the same thing “for example”.

2 Likes